Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenotype-based personalized pharmacologic treatment study in COPD
2015-000982-30Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of salmeterol + fluticasone, salmeterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Occurrence of COPD exacerbation or decline in trough FEV1 during 52-week treatment. Started Jun 2021; status: completed.
02
Drugs
salmeterol + fluticasonesalmeteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-000982-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000982-30.